Colorado’s MedPharm Clears Substantial DEA Hurdle for Federal Cannabis Study License


DENVER–(Small business WIRE)–MedPharm Study, the leader in cannabis investigation and formulation improvement, was notified by the Drug Enforcement Administration (DEA) that it had been chosen to move forward as a single of the initial applicants to be granted a license to develop federally legal cannabis beneath the terms of a new policy statement issued now in the Federal Register.

“This is anything we have been waiting for due to the fact we initial sent in our application in September, 2016, as a single of the initial healthcare develop facilities to apply for a license,” Albert Gutierrez, CEO of MedPharm, mentioned. “Now, lastly, the DEA has observed the value of enabling federally legal grows to get much more active in healthcare cannabis investigation, and do the operate that we truly will need to do for individuals across the nation. It is a genuine game-changer for the entire healthcare cannabis market.”

In a letter to Gutierrez, the DEA stated that MedPharm will be issued a Notice of Proposed Rulemaking, exactly where the corporation will be asked to comment on regulations about increasing cannabis for healthcare investigation. Even so, the DEA has not offered a timetable for when these regulations will be completed. “We at MedPharm stand prepared to help the DEA in any way we can to assist expedite this method, and bring to individuals the ideal good quality, FDA-authorized cannabis that they will need for investigation and remedy as promptly as attainable,” mentioned Gutierrez.

According to the University of Mississippi News, in 1968, the Study Institute of Pharmaceutical Sciences at the University of Mississippi College of Pharmacy was awarded a competitive contract from the government to develop marijuana that could be standardized for investigation. For more than 50 years, it has remained the only cultivation facility licensed by the DEA to offer federally legal cannabis for healthcare researchers, who have reported that cannabis from the university is of such poor good quality that it is basically useless in conducting the lab operate and human trials vital for a trusted FDA-authorized healthcare investigation.

As much more healthcare cannabis investigation ramped up, a increasing group of healthcare cannabis researchers pressured the DEA to open up licensing to other facilities. Then, in August, 2016, the DEA stated that they would commence accepting applications for corporations wanting licenses for legal grows, but practically nothing much more occurred till this June, when a single of the applicants sued the DEA for unreasonable delays, prompting today’s response.

MedPharm is nicely-positioned to operate with the DEA and be amongst the initial providers of federally legal cannabis for healthcare investigation. The application for the license incorporated outlining investigation objectives and developing places exactly where healthcare investigation cannabis is grown particularly for investigation purposes.

About MedPharm:

MedPharm Holdings has a 15,000-square-foot manufacturing, investigation and improvement laboratory and cannabis processing facility in Denver, Colorado. Considering that starting operations in 2016, MedPharm has grown to a employees of 22 individuals, such as a PhD of chemistry and extraction, Dr. Tyrell Towle. Moreover, Scott Karolchyk, the director of formulation improvement at MedPharm, is a member of the Colorado Division of Public Well being and Atmosphere, Marijuana Enforcement Division, Science and Policy Perform Group.

The aim of MedPharm is to offer a trusted clinical impact via the use of nicely-crafted and nicely-researched oil analytics and dosage types. The corporation offers cannabis pharmaceutical-form solutions utilizing Great Manufacturing Practices (GMP) that involve pre-formulation, formulation improvement, tiny scale industrial manufacturing, analytical approach improvement and validation, routine good quality manage evaluation and stability research. MedPharm functions to build pharmaceutical dosage types and generate components using pharmaceutical technologies to be employed in the delivery of cannabis extracts. Take a 360 virtual tour of the MedPharm facility right here:


Latest posts